Saudi Arabia’s record debt sale last week showed that emerging market bonds remain in strong demand with yield-hungry investors. However, the question is whether appetite could reverse as quickly as it has in the past.
The three largest multi-strategy funds for sale in Europe have fared better than most other absolute return funds since the UK’s shock vote to leave the EU. However, the Standard Life GARS fund continues to underperform its peers on a longer-term basis.
Despite the volatility of global financial markets this year and a steady decline in investment returns, confidence among the world’s sovereign wealth funds remains high, a survey by Invesco has found.
Nowhere in Europe are US equities as popular as in Germany. More than half of local fund buyers plan to increase their allocation in the next 12 months. But it would be a terrible idea to do so, fund managers speaking at Expert Investor Deutschland warned.
Investors are fleeing from emerging market debt, and optimism for any recovery in the near term is low, particularly for local currency government bonds.
Fund selectors are divided when determining whether having a star manager at the helm is more likely to lead to long-term performance than a team-based approach.
Smart beta strategies are quickly growing in popularity, according to research commissioned by Invesco Powershares among 400 investors in Europe. However, overall portfolio allocation remains modest and the ways investors use non-market cap weighted index products varies widely across Europe.
The past few weeks have been somewhat of a roller-coaster ride for investors.
Mifid II is, even before implementation, already triggering plenty of unease amongst Europe’s asset management industry.
The rise in commodity prices may have peaked but does this mean the super-cycle is over, and should you buy or sell the asset class? By Manuel-Yutaro Rubio, alternative investment strategies fund analyst, Allfunds Bank
Japan is back in favour. However, many investors are unlikely to give its equities another chance, writes James Smith
As alternative beta products become available to smaller investors, what are the potential benefits and pitfalls of the approach? By Will Jackson
